MOON101 is being developed to treat patients who suffer from peanut allergy and to improve the overall safety and efficacy compared to other available treatment routes. Potential advantages of MOON101 include an anticipated lower applied dose of peanut allergen compared to other products. The MOON101 system delivers peanut allergen via a microneedle (MN) stamp. Microneedle technology is similar to a skin prick test (SPT), which is very well tolerated. The consistent dose delivery should enhance efficacy of the stamp and reduce variability in response. Improvement in safety coupled with improved efficacy is the goal of this product.

Are you interested in earning $20/hour for participating in a research study? You can help the Cognition & Addiction Behavioral Neuroscience Lab at UNC Chapel Hill understand the relationship between sensitivity to alcohol and resting-state brain activity! If you're between 22-50 years old, fluent in English, and medically healthy you may be eligible to participate. We will provide free parking behind Howell Hall through the duration of your session. If you're interested in participating, please email cablab@unc.edu or call us at 919-843-9193 and ask about the TMS study.

Radiation treatment for head and neck cancer can often cause a very dry mouth. This dryness can last for a long time, even after the treatment ends. In our study, we want to see if changing where the radiation is aimed can help with this dryness. If you join, you'll fill out some simple questionnaires and give saliva samples. We'll also check in with you for about a year after your treatment to see how you're doing.

You are being asked to take part in this study because you have triple negative (TN) breast cancer that has spread to your lymph nodes. You are also planning to get chemo-immunotherapy treatment before surgery. Radiation therapy (RT) has been shown to improve the body's immune response against tumors when it is given with a drug called pembrolizumab. The purpose of this study is to find the best and safest dose of radiation (low or high) when given with pembrolizumab. Radiation is measured in Gy (pronounced "gray"). You will be randomly assigned (like flipping a coin) to receive either a low dose RT boost (9 Gy) or a high dose RT boost (24 Gy). The RT will be given with one dose of pembrolizumab. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

We are testing the usability of a health information website that shares easy-to-understand information about prostate cancer. The website is called iPICS. We want to see if the website is helpful for people living in rural areas, especially older adults. By working with public libraries, we hope to learn how to make the website better and easier to use. Our goal is to help people find trustworthy health information so they can make good decisions about their health.

Do you identify as queer? Are you currently family planning? You may be eligible for our study. We are interested in understanding how stress and social support during family planning are related to health outcomes in queer parents and their infants. Study participation will includes interviews, survey completion, and fecal and skin microbiome collection. Compensation provided.

We're looking for healthy, active men and women to take part in a creatine research study. Are you interested in vists the lab for body composition, GI questionnaires, hydration testing and blood draws? Compensation is provided.

Have you ever signed up for health insurance through Healthcare.gov? If you live in North Carolina and are 18 or older, we invite you to share your thoughts! You'll earn $50 for a 45-minute interview with us.

Are you a patient with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)? If so this could be the study for you. The purpose of this study is to investigate if the sonrotoclax in combination with obinutuzumab or rituximab works better and is safe in participants with

If you have Autosomal Dominant Polycystic Kidney Disease (ADPKD), you can help us find out how a new investigational drug works for people like you. Joining this study might not help you directly, but it could help others in the future.